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Abstract
Introduction: The aim of this study was to examine whether circulating levels of the pro-inflammatory
glycoprotein tenascin-C (TNC) are elevated in musculoskeletal disorders including rheumatoid arthritis (RA) and to
assess in RA whether levels are related to clinical disease status and/or patient response to treatment.
Methods: TNC in serum or plasma was quantified by ELISA. Samples from 4 cohorts of RA patients were examined
and compared to normal human subjects and to patients with other inflammatory diseases.
Results: Circulating TNC levels were significantly raised in patients with RA, as well as patients with systemic lupus
erythematosus, idiopathic inflammatory myositis, psoriatic arthritis and ankylosing spondylitis, whilst patients with
Sjogren’s syndrome displayed levels similar to healthy controls. The highest levels of TNC were observed in RA
patients with late stage disease. In early disease TNC levels correlated positively with ultrasound determined
erosion scores. Treatment of early RA patients with infliximab plus methotrexate (MTX) resulted in a transient
decrease in circulating TNC over the first year of therapy. In contrast, TNC levels increased over time in RA patients
receiving MTX alone. In patients treated with infliximab plus MTX, baseline TNC levels significantly correlated with
tender joint counts (TJC) at 18 and 54 weeks after initiation of infliximab therapy.
Conclusions: Raised circulating TNC levels are detected in specific inflammatory diseases. Levels are especially high
in RA where they may act as a biomarker of bone erosion and a predictor of the effect of infliximab on RA patient joint
pain.
Introduction
Rheumatoid arthritis (RA) is a systemic, progressive auto-
immune disease, which affects approximately 1% of the
population worldwide. Early treatment within months of
the onset of persistent symptoms is recommended and
this typically comprises disease-modifying anti-rheumatic
drugs (DMARDs) such as methotrexate (MTX). In many
patients however, DMARD therapy alone is insufficient to
halt disease progression and subsequent treatment with
more targeted therapies is now commonplace. In particu-
lar, agents that target TNF are now in widespread use. A
combination of these biological drugs with MTX can
reduce clinical symptoms and disease progression better
than either agent alone. However, despite this success, a
significant proportion of RA sufferers (approximately 40%)
do not respond to this therapeutic approach and these
patients would benefit from early prescription of alterna-
tive treatments [1].
In combination with a well-defined set of clinical fea-
tures, a panel of biomarkers is routinely used both in the
diagnosis of RA (for example, the presence of rheumatoid
factor and/or anti-citrullinated peptide (CCP) antibodies
in serum) and the monitoring of disease progression (for
example, C-reactive protein (CRP) levels and erythrocyte
sedimentation rate (ESR)). While these markers provide
valuable information to the clinician, they are poorly pre-
dictive of disease prognosis and fail to reliably inform
management decisions for individual patients. Conse-
quently, the identification of further easily assayed biomar-
kers, that are indicative of disease progression or the
response of an individual to treatment, would enable the
clinician to tailor distinct therapies for each patient [2,3].
Tenascin-C (TNC) is a pro-inflammatory extracellular
matrix (ECM) glycoprotein. Its expression in adults is
restricted to sites of tissue injury, particularly during
phases of inflammation and active tissue remodelling.
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Expression of TNC is typically a transient event and tissue
levels return to normal after the completion of tissue repair.
In contrast, persistent expression of TNC is observed in a
number of pathologies associated with inflammation and
tissue remodelling, including autoimmune diseases such as
RA [4,5].
TNC is proposed to act as a damage-associated mole-
cular pattern (DAMP) during RA, where its release upon
joint tissue damage induces the synthesis of pro-inflam-
matory mediators that generate a self-perpetuating cycle
of chronic inflammation leading to further joint damage.
Injection of TNC directly into the murine synovial joint
cavity induces synovial inflammation and in animal mod-
els of RA, TNC-deficient mice show rapid resolution of
joint inflammation and reduced disease severity when
compared to wild type mice [6]. TNC promotes both
innate and adaptive immune responses during joint
inflammation via a number of different mechanisms. We
have previously demonstrated that the C-terminal fibri-
nogen globe of TNC induces pro-inflammatory cytokine
and chemokine production from both primary human
macrophages and synovial fibroblasts isolated from RA
patients by a mechanism that requires toll-like receptor 4
(TLR4) [6]. TNC has also been shown to mediate cyto-
kine synthesis in murine myeloid cells via activation
of a9b1 integrin by a region within the fibronectin type
III-like repeats [7]. Moreover, TNC can stimulate patho-
genic Th17 cell polarization [8,9] and drives IL-17 synth-
esis during murine joint inflammation in vivo [9].
In RA patients TNC is expressed by the synovial fibro-
blasts and infiltrating myeloid cells of the diseased joint
[10,11], where it is deposited as a dense matrix in the
synovial lining layer and where there is also peri-vascular
deposition of TNC [11-14]. Furthermore, elevated levels of
soluble TNC are found in the synovial fluid of RA patients
compared to osteoarthritis (OA) patients and normal
healthy individuals [15,16]. To date no reports have looked
at TNC in serum from RA patients, and it is unclear
whether circulating levels of TNC correlate with disease
parameters such as activity, inflammation, bone destruc-
tion or response to therapy. To address this question we
examined the level of circulating TNC in RA patients
from four independent cohorts, as well as patients with
other inflammatory diseases that exhibit joint inflamma-
tion and arthritis-like symptoms.
Materials and methods
Patients
Patients from four separate RA cohorts were used in this
study. Cohort A: patient inclusion criteria for this trial
have been described previously [17]. Briefly, patients
were required to have a diagnosis of erosive RA accord-
ing to the American college of rheumatology (ACR) 1987
criteria, with symptoms of 0.5 to 3.0 years duration.
Twenty-four patients were randomly assigned to one of
two groups. One group received infusions of infliximab at
5 mg/kg, at weeks 0 (baseline) 2, 6 and then every 8 weeks
through to week 46. The other group received placebo
infusions. Both groups received stable doses of MTX.
Thereafter, at 54 weeks, those patients in the placebo
group received infliximab infusions at weeks 54, 56, 62 and
thereafter every 8 weeks. The original infliximab group
continued to receive infliximab infusions at the same time
points. Blood samples were taken pre-treatment (baseline)
and at weeks 6, 18, 52, 58, 70 and 104. Serum was stored
at -80°C.
Cohort B: inclusion criteria for entry into the trial were
that patients were required to have a diagnosis of RA with
disease activity scored at a moderate level or higher.
Twenty-seven patients received MTX with either placebo
or tranilast (N-(3,4-dimethoxycinnamonyl)-anthranilic
acid), an immune-modulatory compound, at either 75 mg/
kg or 150 mg/kg bis in die (BID). Blood samples were
taken at 0 (baseline), 2, 8 and 16 weeks. EDTA plasma
samples were stored at -80°C.
Cohort C and cohort D were open cohorts of patients
with a diagnosis of RA. Blood samples were collected dur-
ing visits to outpatient departments and serum was stored
at -80°C.
Demographic data were collected from cohorts A and
B (Table 1). Patients were recruited anonymously to
cohorts C and D and as such no demographic informa-
tion is available for these groups. The registration details
of the controlled trials as are follows: Full title of study:
A Phase II, Randomized Multi-Centre, Double-Blind
Study of Tranilast with Concomitant Methotrexate
(MTX) Compared to MTX Alone in Patients with Active
Rheumatoid Arthritis (RA); REC reference number:
09/H0707/26. EudraCT number: 2008-006917-25.
Blood samples from patients with systemic lupus erythe-
matosus (SLE), idiopathic inflammatory myositis (IIM),
Sjogren’s syndrome (SS), psoriatic arthritis and ankylosing
spondyloarthritis (AS) were collected during visits to out-
patients departments and serum was stored at -80°C. All
samples were collected with informed consent in accor-
dance with UK ethical requirements under ethics approval
for the collection of research samples from outpatient
clinics (cohorts C and D, and disease controls) or under
specific ethical approval for clinical trials (cohorts A
and B).
Imaging
In cohorts A and B high-frequency ultrasonography of all
10 metacarpophalangeal joints was performed at weeks 0,
18, 54 and 110 as described previously [17]. Radiographic
evaluation of the hands and feet was performed at base-
line, 54 and 110 weeks and scored for erosions as
described [17].
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Disease activity monitoring
In cohorts A and B, tender joint counts (TJC), swollen
joint counts (SJC), CRP, disease activity score (DAS28)
and ESR were evaluated at all time points. In cohort D,
CRP and anti-CCP were measured at the time of
sampling.
ELISA
Levels of TNC in serum and plasma samples were deter-
mined using the human TNC Large (FN III-C) Assay
ELISA kit from IBL (Fujioka, Japan). The intra- and inter-
assay coefficients of variation for this ELISA are 4.3% and
5.3% respectively, at a value of 3.22 ng/ml. Antibodies to
CCP were measured by ELISA (Eurodiagnostica, Malmo,
Sweden). Cartilage oligomeric matrix protein (COMP) was
measured by ELISA (Biosource, Ghent, Belgium). Type II
procollagen (CPII) and marker of type II collagen cleavage
(C2C) were measured by ELISA (IBEX, Montreal,
Canada). Procollagen III N-terminal propeptide (PIIINP)
was measured by ELISA (USCN, Wuhan, China). Hyaluro-
nan was measured by ELISA (R and D systems, Abingdon,
UK). All assays were performed according to manufac-
turers’ instructions.
SDS PAGE and western blotting
1 μl of serum or plasma was electrophoresed on 4 to 12%
Bis-Tris pre-cast polyacrylamide gels (Invitrogen, Life
Technologies, Paisley, UK). Proteins were transferred
onto nitrocellulose membranes (Amersham, GE Health-
care, Chalfont, UK) and visualised using Ponceau S stain
(Sigma Aldrich, Gillingham, UK). After washing with
TBS/0.01% Tween to remove stain, membranes were
blocked in 5% BSA/TBS-Tween for 1 h at room tempera-
ture and incubated with primary antibody recognising
the N-terminal region of human TNC (MAB 1908,
Merck Millipore, Watford, UK) at 1:1000 dilution for 1 h
at 37°C. Horseradish peroxidase-conjugated anti-mouse
IgG (Dako, Ely, UK) was used as a secondary antibody at
a dilution of 1:3000. Bound antibody was detected using
the enhanced chemiluminescence kit (Amersham, GE
Healthcare) and visualized on Super RX medical x-ray
film (Fuji, Bedford, UK).
Results
Circulating levels of TNC are raised in RA and other
inflammatory conditions
The level of circulating TNC in patients with RA, SLE,
SS, IIM, psoriatic arthritis, and (AS) was quantified to
examine the overall frequency of elevated TNC in rheu-
matic diseases. Levels of TNC were significantly raised
when compared to healthy controls in all conditions
examined, with the exception of SS (Figure 1A, Table 2).
When TNC serum levels from patients with early disease
(cohort A) were compared with those from the other
cohorts with predominantly longer disease duration [17],
significantly lower levels of TNC were observed in the
early stages of disease (Figure 1B), suggesting that circu-
lating levels of TNC increase with duration of disease.
Western blotting revealed that the major form of TNC
present in RA patient samples has a mass of 320 kDa,
(Figure 2A) but minor, smaller, forms of TNC were also
observed in some patients (Figure 2B). These bands were
not present in normal healthy individuals, nor in blots
probed with secondary antibody alone (data not shown).
Circulating TNC correlates with joint erosion in RA
patients
Given that circulating TNC was raised in RA patients, we
examined whether levels of TNC correlated with tradi-
tional markers of disease activity and with other potential
markers of disease process. Table 3 shows that there was
no significant correlation between TNC levels and these
biomarkers at baseline sampling. In cohort A both x-ray-
and ultrasound-determined erosion data were available.
We noted an association between higher baseline TNC
levels and higher x-ray-derived erosion scores in baseline
samples. Whilst this was not found to be statistically signif-
icant (P = 0.08), analysis of ultrasound erosion data (con-
sidered to be more sensitive for detection of erosions in
early RA) from the same dataset revealed a significant cor-
relation between TNC level at baseline and baseline ultra-
sound erosion scores (r = 0.493, P = 0.0144) (Figure 3A).
In particular, those patients with abnormal levels of TNC
at baseline showed significantly higher ultrasound erosion
scores than those with baseline normal values at this time
point (Figure 3B). These data suggest that circulating levels
of TNC do not correlate with currently used clinical mar-
kers of disease activity but may be an indicator of erosive
joint damage in RA patients.
Table 1 Demographic data from cohorts A and B
Cohort A Cohort B
Age Age
20 38 68 39 64 30 54
60 60 53 57 49 65 66
71 44 53 68 74 66 61
61 49 48 68 64 68 56
46 52 75 51 57 47 80
56 59 73 51 76 52
39 66 53 58 69 75
68 51 59 67 34 78
59 44 60 66 69 66
47 68 66 74 34 54
71 45 55 56 71 55
Age is shown in years. The mean age was 53.36 years (+/- 12.63) for cohort A
and 60.24 years (+/-11.63) for cohort B (+/-SD). The median age for cohort A
was 54.00 years and for cohort B, 61.00 years. Patients in both cohorts were
predominantly female (72.7% in cohort A and 73.5% in cohort B).
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Infliximab treatment transiently reduces serum TNC levels
Patients in cohort A were divided into two treatment
groups, one receiving MTX plus infliximab (5 mg/kg)
treatment for 1 year, the other receiving MTX plus pla-
cebo for 1 year [17]. After this time both groups received
infliximab (5 mg/kg) therapy for a further year. Serum
samples from both groups of patients were collected at
regular intervals and the effect of treatment on TNC levels
was monitored. Patients receiving infliximab + MTX treat-
ment showed a decrease in their levels of circulating TNC
(Figure 4A). In contrast, patients receiving only MTX
showed a steady increase in the level of circulating TNC
between 0 and 54 weeks. It is interesting to note that upon
receiving infliximab in the second year of the trial, TNC
levels dropped in these patients as well (Figure 4B). In
both cases, this infliximab-induced decrease in TNC was
transient, with levels rising again approximately 1 year
after initiation of infliximab treatment, despite continued
therapy (Figure 4A, B). In cohort B, patients treated with
MTX alone or with MTX plus tranilast at either 75 mg/kg
BID or 150 mg/kg BID showed a rise in TNC levels similar
to that observed in cohort A for MTX alone (Figure 4C,
D). These data indicate that the decrease in serum TNC in
patients receiving infliximab is due to a specific action of
this drug or class of drugs targeting TNF.
High serum TNC is predictive of unresolved joint
tenderness in infliximab-treated patients
Despite the major advances provided by therapy with anti-
TNF agents such as infliximab, a significant proportion of
patients treated with anti-TNF agents do not respond, and
continue to acquire joint erosions and increase in disease
activity score 28 (DAS28). In the light of the correlation of
TNC levels with erosion scores and the effect of infliximab
Figure 1 Circulating tenascin-C (TNC) is raised in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic
inflammatory myositis (IIM), psoriatic arthritis (PSA) and ankylosing spondylitis (AS) patients but not in Sjogren’s syndrome (SS) and
TNC serum concentration increases with disease duration in RA. (A) TNC levels were determined by ELISA in serum samples from healthy
controls (N) (n = 19), and patients with RA (n = 40), SLE (n = 24), IMM (n = 25), SS (n = 24), PSA (n = 6) or AS (n = 14). Each point represents the mean
value of duplicate samples from an individual. Significant differences between patients and healthy controls were analysed by Mann-Whitney two-
tailed analysis; ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns = not significant. (B) The RA cohorts were grouped according to disease duration
into early (duration < 3 years) and late (duration > 3 years) RA. TNC levels from serum were determined by ELISA. Bars represent the mean plus
standard error of the mean (SEM) from pooled data from 19 controls (N), 24 early RA or 16 late RA patients; *P < 0.05 (unpaired t-test).
Table 2 Circulating levels of tenascin-C (TNC) are raised in a number of inflammatory conditions
Sample Mean TNC
(ng/ml)
Number of samples P-value
(compared to N)
Patients with abnormal TNC, %
Normal healthy subjects (N) 20.7
(95% CI = 33)
19
Rheumatoid arthritis (RA) 118.2 40 < 0.0001 82.5
Systemic lupus erythmatosus (SLE) 77.8 24 < 0.0001 83.3
Sjogren’s syndrome (SS) 16.7 24 0.3489 8.3
Idiopathic inflammatory myositis (IIM) 69.8 25 0.0008 64.0
Psoriatic arthritis (PSA) 64.7 6 0.0026 100.0
Ankylosing spondylitis (AS) 53.8 13 0.0006 76.9
Blood was taken from normal healthy controls (N) and patients with RA, SLE, SS, IIM, PSA and AS, and TNC levels were determined in serum by ELISA. The 95%
confidence interval (CI) of TNC levels in normal healthy subjects was determined to be 33 ng/ml. The P-value was determined by Student’s t-test.
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on circulating TNC levels, we asked whether the level of
TNC served as a predictor of future disease progression in
infliximab-treated patients. There was no relationship
between baseline level of TNC or change in TNC level at
weeks 18 or 52 after commencement of therapy and
response to infliximab. However, a significant correlation
was seen between the level of TNC at baseline and the
subsequent TJC score in infliximab-treated patients at
both 16 to 18 and 54 weeks after the start of treatment
(Figure 5). Thus, these data suggest that patients with
higher levels of TNC before the initiation of infliximab
therapy are more likely to have unresolved joint tender-
ness despite infliximab therapy.
Discussion
Over the last two decades the advent of drugs such as
anti-TNF used in combination with concomitantly admi-
nistered MTX has revolutionized the standard of care of
many RA patients. However, individual RA patients differ
significantly in the clinical manifestation of their disease,
Figure 2 Western blotting of circulating tenascin-C (TNC) in rheumatoid arthritis (RA) patients. (A) In baseline samples from RA patients
one predominant TNC band of 320 kDa was observed (n = 18). Corresponding TNC levels detected in the same samples by ELISA are shown in
pg/ml under the blot. Low levels of TNC were detected in healthy control plasma (N). rhTNC, 0.05 μg human recombinant TNC. (B) In addition
to the major band detected at 320 kDa, bands of MW 219, 201, 190 and 156 kDa were present in the plasma of some RA patients upon western
blotting with anti-TNC antibodies (TNC). Ponceau S staining of the same membrane shows equivalent protein loading for each RA sample.
Table 3 Circulating levels of tenascin-C (TNC) do not correlate with any traditional biomarkers of disease in
rheumatoid arthritis (RA)
Cohort Biomarker Correlation with TNC at baseline?
Cohort A CRP No
Anti-CCP No
ESR No
Markers of bone and cartilage metabolism: COMP, CPII, C2C, PIIINP, hyluronan No
Clinical score: TJC, SJC No
Disease activity: DAS28 No
Cohort B CRP No
Clinical score: TJC, SJC No
Disease activity: DAS28 No
Cohort C CRP No
Anti-CCP No
Cohort D N/A N/A
TNC levels at baseline (entry into trial) in four separate cohorts of RA patients were analysed by ELISA. CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated
peptide antibody; COMP, cartilage oligomeric matrix protein; CPII, type II pro collagen; C2C, marker of type II collagen cleavage; ESR, erythrocyte sedimentation
rate; PIIINP, procollagen III N-terminal propeptide; TJC, tender joint count; SJC, swollen joint count; DAS28, disease activity score 28; N/A, data not available.
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Figure 3 Levels of circulating tenascin-C (TNC) show a positive correlation with ultrasound-determined erosion scores prior to anti-
tumour necrosis factor (TNF) therapy. (A) Levels of TNC in baseline serum samples from early rheumatoid arthritis (RA) patients (n = 24) in cohort
A were determined by ELISA and compared with erosion scores at baseline as determined by high frequency ultrasonography of 10 MCP joints.
Significance was determined using spearman rank correlation analysis. (B) Patients with abnormal serum levels of TNC (> 33 ng/ml) (n = 21) show
higher ultrasound-determined erosion scores at baseline than patients with normal (≤ 33 ng/ml) TNC (n = 3); * P < 0.05 (t-test with Welch’s correction).
Figure 4 In rheumatoid arthritis (RA) patients, infliximab therapy results in a temporary reduction in serum tenascin-C (TNC), while
treatment with methotrexate (MTX) or tranilast does not. Blood was taken from RA patients at entry into their trial (week 0) and at various
weekly intervals afterwards. Serum (cohort A) or plasma (cohort B) was collected and TNC levels were measured by ELISA. In cohort A patients
received infliximab therapy immediately (n = 12) (A) or after 52 weeks (n = 12) (B). Arrow shows the start of infliximab therapy. In cohort B,
patients received either MTX alone (C) or tranilast therapy at 75 mg/kg or 150 mg/kg (D) from week 0 (n = 9).
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as well as in their response to treatment with these drugs.
As such, disease diagnosis would ideally be followed by
early implementation of the therapeutic regime most
likely to be effective in reducing the inflammatory burden
in each patient. One major obstacle to this approach is
that existing biomarkers of disease cannot predict disease
prognosis or patient response to treatment.
Here we examined whether detection of circulating
levels of TNC, a pro-inflammatory glycoprotein, may be
useful in this respect. TNC is not expressed, or is
expressed only at very low levels, in most healthy adult tis-
sues. Little TNC is observed in healthy joints; however,
high levels of TNC are detected in the synovia of RA
patients [10-14]. Consistent with these data, we found little
TNC in the serum of normal healthy subjects, but high
levels were detected in the serum of RA patients; more
than 80% of patients with RA showed circulating levels of
TNC greater than those found in healthy controls. We
also observed elevated TNC levels in patients with a range
of inflammatory diseases, all of which are associated with
chronic arthritis. Thus, raised serum TNC is not specifi-
cally associated with RA. Furthermore, raised serum levels
of TNC have been reported in diseases with no known
arthritic manifestation, including cryptogenic pneumonia,
cardiovascular diseases such as myocardial infarction and
dilated cardiomyopathy [18,19], chronic hepatitis C [20],
inflammatory bowel disease (IBD) [21] and sepsis [22].
Notably, however, we found that patients with SS exhib-
ited no significant increase in serum TNC over healthy
controls. Similarly, serum TNC is elevated in some can-
cers, such as melanoma [23] and ovarian cancer [24], but
not in others, such as small lung cell carcinoma [25,26].
These data suggest that high serum TNC is associated
with pathological tissue inflammation and remodelling in
a wide variety of diseases.
TNC is a large, multimodular molecule. It comprises a
number of distinct domains, including an assembly
domain, a series of fourteen-and-a-half epidermal growth
factor-like repeats, a series of up to seventeen fibronectin
type III-like repeats (TNIII), and a fibrinogen-like globe.
TNC is encoded by a single gene that is alternatively
spliced to create monomers ranging in size from 190 to
320 kDa. This occurs specifically in the TNIII domains;
eight of these are constitutively expressed (TNIII1-8) and
nine can be alternatively spliced (A1-4, B, AD2, AD1, C
and D) [4,27]. There is considerable tissue and disease
stage-specific variation in TNC isoform expression. This
has been best studied in tumours, where the expression of
specific splice variants can predict survival of patients with
chondrosarcoma or response to tamoxifen in patients with
breast cancer [5]. Here, we found that the predominant
variant of TNC in RA serum was 320 kDa in mass, sug-
gesting that this constitutes the large isoform possessing
all nine alternatively spliced TNIII repeats. The functional
relevance of every alternatively spliced domain is not clear,
but their inclusion in TNC variants expressed in RA may
contribute to disease pathogenesis. For example, splicing
in domains B and D promotes tumour cell proliferation
and invasion, and repeats A to D have been shown to con-
fer tumour cell survival (reviewed in [5]). In addition to
the major band at 320 kDa, we also observed minor bands
of a lower mass in some patients. These data could suggest
that a small amount of differently spliced TNC isoforms
can be expressed in RA, that a minor proportion of circu-
lating TNC is subject to proteolytic degradation or that a
minor proportion of circulating TNC derives from proteo-
lytic cleavage of the intact ECM of the RA synovium.
Further studies are needed to identify more precisely the
post-transcriptional modification of TNC occurring in the
joints in RA.
Localized TNC expression has previously been shown to
associate with disease activity; elevated levels of TNC in
the tumour stroma correlate with metastasis and poor
prognosis in both breast and brain cancer [27,28]. In the
Figure 5 Tenascin-C (TNC) level at baseline is predictive of future tender joint count in rheumatoid arthritis (RA) patients at both 16
to 18 weeks and 54 weeks after commencing infliximab therapy. Serum from RA patients in cohort A at baseline (entry into the trial) was
analysed for TNC level by ELISA. TNC levels are shown with practitioner-determined tender joint counts in these patients at 16 to 18 weeks (A)
and 54 weeks (B) after receiving infliximab therapy (n = 24). Significance was determined by spearman rank correlation analysis.
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heart, both cardiac tissue levels of TNC in the extracellular
matrix and circulating TNC correlate with disease severity
in acute myocardial infarction, dilated cardiomyopathy
and myocarditis [27]. Furthermore, high levels of circulat-
ing TNC in chronic hepatitis C adversely correlate with
disease outcome [20], and serum TNC levels in patients
with ulcerative colitis (UC) correlate with disease activity
and reflect improved disease symptoms after treatment of
both UC and IBD [21]. When we examined a link between
raised serum TNC and RA disease activity, we found that
TNC levels specifically correlated with joint erosion, but
not with any other disease parameter. Thus, circulating
TNC is not associated with clinical markers of inflamma-
tion or with DAS28 but may be an indicator of erosive
joint damage in RA patients.
TNC expression is specifically associated with sites of
tissue injury where it is induced in response to a range of
stimuli, including mechanical stress, pro-inflammatory
cytokines, growth factors, hypoxia and reactive oxygen
species [4]. High levels of circulating TNC in patients with
erosive RA therefore may appear as a consequence of
advanced joint tissue destruction. The expression of TNC
itself however provokes further tissue injury, potentially
via a number of different mechanisms, suggesting that
raised serum TNC in RA may serve both as cause and
effect of active joint erosion. In murine models of joint dis-
ease TNC drives the synthesis of pro-inflammatory cyto-
kines and chemokines such as TNF, IL6 and IL8 [9],
which in turn mediate the synthesis of tissue-destructive
enzymes. TNC can also directly promote collagenase
expression in rabbit synovial fibroblasts [29]. Moreover,
TNC is required for the induction of IL-17 in inflamed
murine joints [9], a cytokine that directly mediates joint
tissue degradation by activating bone resorbing osteoclasts,
inhibiting cartilage matrix synthesis and inducing pro-
teases [30]. IL-17 is also found at high levels in RA
patients with advanced levels of joint damage [30]; it has
also been shown to drive autonomous, TNF-independent
erosive disease in mice [31,32] and TNF therapy is anec-
dotally reported to prevent erosion less effectively in RA
patients with high IL-17 levels [30]. As such, patients with
high serum TNC may benefit from therapeutic blockade
of IL-17 activity rather than inhibition of TNF.
Our data reveal that TNC levels increase over the course
of RA progression. We also observed that infliximab treat-
ment of RA produces a rapid reduction in serum TNC
levels, while patients receiving MTX alone have a progres-
sive increase in circulating TNC. TNF induces TNC
expression in chondrocytes and fibroblasts [33,34] and so
our data may reflect the fact that inactivation of TNF
removes a stimulator of TNC expression. This would
explain the observation that treatment with tranilast is
unable to modulate TNC expression in the same way as
infliximab. However, the effect of infliximab on TNC levels
is temporary causing only a transient drop in TNC, which
returns to abnormal levels after 1 year. This rebound in cir-
culating TNC despite continued treatment, suggests that
alternative mechanisms of TNC induction can dominate
during TNF suppression. It may be interesting to examine
the effect of other biological drugs on TNC levels in RA
patients. In particular, as levels of TNC correlate with
those of IL-6 in the RA synovium [10], and as IL-1 has
been shown to induce TNC expression in cultured synovial
fibroblasts [11], tocilizumab and anakinra may have similar
effects on TNC expression.
Conclusions
Despite the improved outcome for many RA patients
treated with anti-TNF agents such as infliximab, approxi-
mately 30 to 50% of patients do not benefit, and their dis-
ease continues to progress. We found that in patients
treated with infliximab and MTX, high serum TNC was
predictive of a poor response of joint tenderness to inflix-
imab. This finding that the level of TNC in serum before
beginning infliximab treatment acts as a predictor of ten-
der joint count as far as one year in advance, may allow
us to begin to distinguish between patients who are likely
to benefit from anti-TNF treatment.
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